Abstracts Archive - Page 738 of 2607 - ACR Meeting Abstracts

Abstract Number: 0493 • ACR Convergence 2021
Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study
Ehizogie Edigin¹, Precious Eseaton², Chinenye Osuorji³, Nneka Chukwu⁴, Oluyemisi Amoda⁵, Kolade Olabode⁶ and Augustine Manadan⁷, ¹Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin, Benin, Nigeria, ³Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, ⁴Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁵Internal Medicine, Brookdale University hospital and medical center, New York, NY, ⁶College of Public Health, Kent State University, Kent, OH, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Longitudinal data are limited on SLE flare hospitalizations. This study aims to study longitudinal trends of SLE flare hospitalizations in the last 2 decades…
Abstract Number: 0494 • ACR Convergence 2021
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Sharon Dowell¹, Huifeng Yun², Jeffrey Curtis³, Lang Chen⁴, Manuela Pedra-Nobre⁵, Dianne Wollaston⁶, SAWSAN NAJMEY⁷, Cynthia Lawrence-Elliott⁸, Theresa Lawrence-Ford⁹, Heather North¹⁰, Robin Dore¹¹, Soha Dolatabadi¹², Thaila Ramanujam¹³, Anne Winkler¹⁴, Stacy Kennedy¹⁵, Stephanie Ott¹⁶, Stephanie Ledbetter¹⁷, Grace Wright¹⁸ and Gail Kerr¹⁹, ¹Howard University College of Medicine, Washington, DC, ²University of Alabama Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama, Birmingham, AL, ⁵North Jersey Rheum. Center, Westfield, NJ, ⁶Memorial Advanced Rheumatology, Houston, TX, ⁷Midstate Rheumatology Center, PA, Freehold, NJ, ⁸North Georgia Rheum Group, Atlanta, GA, ⁹North Georgia Rheum Group, Atlanta, MD, ¹⁰Pardee UNC, Hendersonville, NC, ¹¹Robin K. Dore, MD Inc, Tustin, CA, ¹²Soha Dolatabadi, MD, Los Angeles, CA, ¹³Santa Cruz Rheumatology, Inc., Santa Cruz, CA, ¹⁴Winkler Medical Practice, Springfield, MO, ¹⁵Rowan Diagnostic Clinic, Concord, NC, ¹⁶Fairfield Medical Center, Carroll, OH, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ¹⁹Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
Abstract Number: 0495 • ACR Convergence 2021
Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Racial/ethnic disparities have also been associated with an increased burden of multimorbidity.…
Abstract Number: 0496 • ACR Convergence 2021
Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
Satoshi Ebata¹, Ayumi Yoshizaki¹, Koji Oba², Kosuke Kashiwabara³, Keiko Ueda³, Yukari Umemura⁴, Takeyuki Watadani⁵, Takemichi Fukasawa¹, Shunsuke Miura¹, Asako Yoshizaki-Ogawa¹, Yoshihide Asano¹, Naoko Okiyama⁶, Masanari Kodera⁷, Minoru Hasegawa⁸ and Shinichi Sato¹, ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Biostatistics, School of Public Health, Graduate School of Medicine, and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research Support Center, The Tokyo University Hospital, Tokyo, Japan, ⁴Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, ⁵Department of Diagnostic Radiology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Ibaraki, Japan, ⁷Department of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Aichi, Japan., Aichi, Japan, ⁸Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan., Fukui, Japan
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease belonging to collagen diseases, characterized by fibrosis of various organs including the skin and lungs, and…
Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Victor Tapson¹, Steven Nathan², Reda Girgis³, James Runo⁴, Remzi Bag⁵, Arunabh Talwar⁶, Peter Smith⁷, Lisa Edwards⁷, Christine Park⁷ and Aaron Waxman⁸, ¹Cedars-Sinai, Los Angeles, CA, ²Inova Fairfax, Falls Church, VA, ³Michigan State University, Lansing, MI, ⁴University of Wisconsin, Madison, WI, ⁵University of Chicago, Chicago, IL, ⁶Hofstra Northwell School of Medicine, Hempstead, NY, ⁷United Therapeutics Corporation, Durham, NC, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…
Abstract Number: 0498 • ACR Convergence 2021
Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Robert Spiera¹, Dan Furst², Tracy Frech³, Masataka Kuwana⁴, Laura Hummers⁵, Wendy Stevens⁶, Suzanne Kafaja⁷, Eun bong Lee⁸, Scott Constantine⁹, Nancy Dgetluck⁹, Barbara White¹⁰ and Christopher Denton¹¹, ¹Hospital for Special Surgery, New York, NY, ²University of California Los Angeles, Los Angeles, CA, ³University of Utah, Salt Lake City, UT, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Johns Hopkins Univerisity, Baltimore, MD, ⁶St Vincent's Hospital, Melbourne, Australia, ⁷University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ⁸Seoul National University Hospital, Seoul, Republic of Korea, ⁹Corbus Pharmaceuticals, Inc., Norwood, MA, ¹⁰Corbus Pharmaceuticals, Norwood, MA, ¹¹University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Treatment of dcSSc is evolving, with limited information on relative efficacies of different immunosuppressive therapies (IST). Our hypothesis was that patients on MMF have…
Abstract Number: 0499 • ACR Convergence 2021
Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome instrument devised to assess the severity and impact of SSc-RP.…
Abstract Number: 0500 • ACR Convergence 2021
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
Monica Yang¹, Vivien Goh², Monica Espinoza³, Yiwei Yuan⁴, Julia Lee⁵, Mary Carns⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield⁹ and Monique Hinchcliff¹⁰, ¹University of California San Francisco, San Francisco, CA, ²Northwestern University, Chicago, IL, ³Geisel School of Medicine, Hanover, NH, ⁴Dartmouth College, Hanover, NH, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹Geisel School of Medicine, Lebanon, NH, ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Although two subsets in systemic sclerosis (SSc) have been identified based on degree of skin disease, the current classification system, limited vs. diffuse cutaneous,…
Abstract Number: 0501 • ACR Convergence 2021
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
Vishal Kakkar¹, Rebecca Ross², Ranjitha Karanth³, Sumit Lahiri⁴, Panji Mulipa¹, Pamela Hughes⁵, Brendan Clarke⁵, Clive Carter⁵, Mark Lobb⁵, Sinisa Savic⁶ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²LIRMM University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Transplant and Cellular Immunology, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a rare connective tissue disease with multi-systemic involvement, which at times requires the use of immunosuppressive medication. None of the…
Abstract Number: 0502 • ACR Convergence 2021
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Benjamin Hur¹, Matthew Koster¹, Jin Sung Jang¹, Kenneth Warrington² and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota
Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 0504 • ACR Convergence 2021
Longitudinal Patterns of Vascular Inflammation in Large-vessel Vasculitis
Hugh Alessi¹, Kaitlin Quinn², Mark A. Ahlman³, Yiming Luo³, Elaine Novakovich³ and Peter Grayson⁴, ¹National Institutes of Health, Bethesda, Maryland, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The two main forms of large vessel vasculitis (LVV), giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), are clinically heterogenous diseases with variable disease…
Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Despina Michailidou¹, Tianyu Zhang², Pavlos Stamatis³ and Bernard Ng⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
Abstract Number: 0506 • ACR Convergence 2021
Transcriptomic Changes Induced by Mavrilimumab versus Tocilizumab in ex-vivo Cultured Arteries from Patients with Giant-cell Arteritis
Marc Corbera- Bellalta¹, Farah Kamberovic¹, Farran Araujo², Roser Alba-Rovira¹, Georgina Espigol-Frigolé¹, Marco A. Alba¹, Sergio Prieto-Gonzalez¹, José Hernández-Rodríguez¹, Patricia Pérez-Galán², Alexandra Joseph³, John F Paolini³ and Maria C. Cid¹, ¹Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, ²Department of Hemato-Oncology (IDIBAPS), Barcelona, Spain, ³Kiniksa Pharmaceuticals Corp., Lexington, MA
Background/Purpose: Giant cell arteritis (GCA) is a chronic disease, and affected patients suffer from relapses and glucocorticoid (GC)-related toxicity. Targeted therapies are emerging with the…
Abstract Number: 0507 • ACR Convergence 2021
Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial
Michael Bonelli¹, Helga Radner¹, Josef Smolen¹, Martina Durechova¹, Jutta Stieger², Rusmir Husic³, Andreas Kerschbaumer¹, Christian Dejaco⁴ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Medical University of Graz, Graz, Austria, ⁴Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, Brunico, Italy, ⁵Medical University Vienna, Vienna, Austria
Background/Purpose: PMR is the second most common inflammatory rheumatic disease of people aged 50 years or older. Glucocorticoid therapy is highly effective, but many patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].